GSG Advisors LLC Increases Stock Position in Johnson & Johnson $JNJ

Key Points

• GSG Advisors LLC increased its stake in Johnson & Johnson by 71.4% in the second quarter, owning a total of 8,884 shares valued at approximately $1.36 million.
• Johnson & Johnson reported a quarterly earnings per share (EPS) of $2.77, surpassing analysts' expectations, with revenue reaching $23.74 billion.
• The company declared a quarterly dividend of $1.30 per share, contributing to an annualized dividend yield of 2.9%, with a payout ratio of 55.61%.

GSG Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 71.4% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,884 shares of the company's stock after purchasing an additional 3,701 shares during the period. GSG Advisors LLC's holdings in Johnson & Johnson were worth $1,357,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Mirador Capital Partners LP lifted its stake in shares of Johnson & Johnson by 5.4% in the 2nd quarter. Mirador Capital Partners LP now owns 4,853 shares of the company's stock worth $741,000 after purchasing an additional 248 shares during the period. StrongBox Wealth LLC lifted its stake in shares of Johnson & Johnson by 3.4% in the 2nd quarter. StrongBox Wealth LLC now owns 3,584 shares of the company's stock worth $548,000 after purchasing an additional 118 shares during the period. Aaron Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson by 3.8% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 20,826 shares of the company's stock worth $3,181,000 after purchasing an additional 753 shares during the period. Divergent Planning LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $548,000. Finally, Balefire LLC lifted its stake in shares of Johnson & Johnson by 35.1% in the 2nd quarter. Balefire LLC now owns 4,735 shares of the company's stock worth $723,000 after purchasing an additional 1,231 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.5%

JNJ stock opened at $176.48 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a fifty day moving average price of $171.67 and a 200 day moving average price of $161.46. The firm has a market cap of $425.02 billion, a PE ratio of 18.87, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Bank of America raised their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.